The ARISE webinar series on Sickle Cell Disease continues. The webinar “Newborn Sickle Cell Disease Screening“ has been organised and it will be held on Wednesday 22nd July, 2020 at 05:00 PM (BST).
The article “Evaluation of the effectiveness and safety of Deferiprone compared to Deferasirox in pediatric patients with hemoglobinopathies (DEEP-2)” was recently published on The Lancet Haematology Journal.
Lately, a set of webinars focused on Sickle Cell Disease have been organised within the ARISE project. A new one will be held on 24th June 2020 at 03:30 PM BST and will address the paediatric to adult transition care for patients with sickle cell disease.
Aliyu Mande, health information officer at Ahmadu Bello Teaching Hospital, Zaria (Nigeria), replied to some questions about the COVID-19 management in his country with a focus on Sickle Cell Disease (SCD) patients. The interview is in the context of the FGB activities within the ARISE project.
Do not miss the new webinar “Paediatric multisystem inflammatory syndrome temporally associated with COVID-19 and Sickle Cell Disease – what is the link?” organised within the ARISE project to be held on Monday 15th June at 06:00 PM CEST (05:00 PM UK time).
The second session of the webinar, to be held on Thursday 28th May, 2020 at 04:00 PM (UK time), will be the occasion to discuss with some relevant experts in the field to better understand the impact of COVID-19 on the SCD population, drawing conclusions from both the US and Lebanon. The emotional impact of the disease will be addressed as well.
In collaboration with the partners of the ARISE project that the Foundation coordinates, the webinar “COVID-19 and Sickle Cell Disease: the current scenario” has been organised. The first session of the webinar will be held on Tuesday 19th May, 2020 at 04:00 PM (UK time).
COVID-19 pandemic is a health emergency involving all the world and the rare disease community is not excluded. Among the patients exposed to major risks, there are those treated with immunosuppressive drugs and those affected by respiratory diseases, but most of all those who have one or more complications affecting several organs and systems.
Fondazione Italiana “L. Giambrone”, involved in the research and treatment of the thalassaemia, is pleased to present, in collaboration with the Italian Associations Advocacy Council (IAAC), the second cycle of the empowerment workshops addressed to patients, healthcare professionals and associations representatives.
Sickle Cell Disease (SCD) has been recognized as a global public health issue; it affects millions of people, including children, throughout the world. More than 300.000 children are born each year with SCD and most of them in African countries.
Recent posts in Haemoglobinopathies